JP2014508715A5 - - Google Patents

Download PDF

Info

Publication number
JP2014508715A5
JP2014508715A5 JP2013540569A JP2013540569A JP2014508715A5 JP 2014508715 A5 JP2014508715 A5 JP 2014508715A5 JP 2013540569 A JP2013540569 A JP 2013540569A JP 2013540569 A JP2013540569 A JP 2013540569A JP 2014508715 A5 JP2014508715 A5 JP 2014508715A5
Authority
JP
Japan
Prior art keywords
monoclonal antibody
agent according
als agent
tnfα monoclonal
als
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013540569A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014508715A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/JP2012/056217 external-priority patent/WO2012121403A1/en
Publication of JP2014508715A publication Critical patent/JP2014508715A/ja
Publication of JP2014508715A5 publication Critical patent/JP2014508715A5/ja
Pending legal-status Critical Current

Links

JP2013540569A 2011-03-07 2012-03-06 筋萎縮性側索硬化症の治療方法 Pending JP2014508715A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161449753P 2011-03-07 2011-03-07
US61/449,753 2011-03-07
PCT/JP2012/056217 WO2012121403A1 (en) 2011-03-07 2012-03-06 The method of treating amyotrophic lateral sclerosis

Publications (2)

Publication Number Publication Date
JP2014508715A JP2014508715A (ja) 2014-04-10
JP2014508715A5 true JP2014508715A5 (https=) 2015-04-02

Family

ID=46798352

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013540569A Pending JP2014508715A (ja) 2011-03-07 2012-03-06 筋萎縮性側索硬化症の治療方法

Country Status (4)

Country Link
US (1) US20130344081A1 (https=)
EP (1) EP2683404A4 (https=)
JP (1) JP2014508715A (https=)
WO (1) WO2012121403A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2811948C (en) * 2010-11-01 2018-11-06 Tact Ip Llc Etanercept for use in the treatment of chronic brain injury
AU2013315007A1 (en) 2012-09-17 2015-04-09 The Research Institute At Nationwide Children's Hospital Compositions and methods for treating amyotrophic lateral sclerosis
WO2015069647A1 (en) * 2013-11-05 2015-05-14 The Research Institute At Nationwide Children's Hospital COMPOSITIONS AND METHODS FOR INHIBITING NF- kB AND SOD-1 TO TREAT AMYOTROPHIC LATERAL SCLEROSIS
JP2021525796A (ja) * 2018-05-25 2021-09-27 レヴァレシオ・コーポレーション 神経疾患の阻害
EP3843673B1 (en) 2018-08-31 2026-04-15 Revalesio Corporation An oxygenated fluid for use for the treatment of stroke
CN113573778B (zh) * 2018-11-16 2025-05-13 拉帕治疗有限公司 使用诱导性调节性T（iTREG）细胞进行的ALS治疗
EP4076429A4 (en) * 2019-12-16 2024-01-31 The Regents of the University of California Compositions and methods for treating neuromuscular disorders
CN114712503B (zh) * 2021-10-09 2023-05-26 浙江大学 c-Abl抑制剂在制备预防和/或治疗肌萎缩性侧索硬化症药物中的应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) * 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
DK0929578T3 (da) 1996-02-09 2003-08-25 Abbott Lab Bermuda Ltd Humane antistoffer, der binder human TNFalfa
US6177077B1 (en) * 1999-02-24 2001-01-23 Edward L. Tobinick TNT inhibitors for the treatment of neurological disorders
US6379666B1 (en) * 1999-02-24 2002-04-30 Edward L. Tobinick TNF inhibitors for the treatment of neurological, retinal and muscular disorders
US20030206898A1 (en) * 2002-04-26 2003-11-06 Steven Fischkoff Use of anti-TNFalpha antibodies and another drug
US9605064B2 (en) * 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
MX345039B (es) * 2008-06-25 2017-01-16 Esbatech Alcon Biomed Res Unit Anticuerpos estables y solubles que inhiben el tnfa.

Similar Documents

Publication Publication Date Title
JP2014508715A5 (https=)
HRP20192202T1 (hr) Acc inhibitori i njihove upotrebe
EP3449940A4 (en) ANTIBODY PREPARATION
JP2015125255A5 (https=)
JP2015505555A5 (https=)
JP2011256183A5 (https=)
JP2012031178A5 (https=)
MX373549B (es) Derivado de pirazol amida.
MA40682A (fr) Anticorps anti-ox40 et procédés d'utilisation correspondants
EA201890239A2 (ru) Фумараты как пролекарства и их применение при лечении различных заболеваний
EP2771031A4 (en) ALPHA SYNNUCLEIN DETECTING HUMANIZED ANTIBODIES
EP2813568A4 (en) MODIFIED FC ANTIBODY REGIONS
EA201500852A1 (ru) Формы метил {4,6-диамино-2-[1-(2-фторбензил)-1н-пиразоло[3,4-в]пиридино-3-ил]пиримидино-5-ил}метил карбамата
MX386298B (es) Composicion farmaceutica que comprende adalimumab.
EP2949647A4 (en) DEUTERATED PHENYLAMINOPYRIMIDIN COMPOUND AND PHARMACEUTICAL COMPOSITION THEREWITH
FR2997852B1 (fr) Composition cosmetique contenant un acetate d'un compose d'aminoacide.
EA201400165A1 (ru) Частицы на основе полиакрилата, которые содержат активное соединение
WO2015050891A3 (en) Methods for assessing status of post-transplant liver and determining and administering specific treatment regimens
MX392001B (es) Composiciones fertilizantes y métodos para hacer y utilizar las mismas.
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
MX386861B (es) Composiciones inhibidoras de nitrificación microencapsuladas.
EP2810659A4 (en) MOUTH-CATCHING TABLET WITH GRANULATE TO COVER THE BITTER TASTE
EP2670435A4 (en) USE OF MONOCLONAL ANTIBODIES AGAINST DKK1 FOR THE TREATMENT OF LIVER CANCER
PH12017500461B1 (en) Humanized monoclonal antibody, inhibiting the enzymatic activity of vascular endothelial lipase
EP2847218A4 (en) APOE4 ANTIBODY FOR THE TREATMENT OF NEURODEEGENERATIVE DISEASES